Liven Pharma Limited held an executive briefing session outlining its corporate profile, strategic vision, and future growth plans.
- The session covered the company's transformation into a public limited entity and its commitment to high-quality pharmaceutical manufacturing.
- Key highlights included a focus on injectables, psychotropics, and specialty formulations, with over 120 registered molecules.
- Liven aims to establish itself as a leading pharmaceutical manufacturer in the Sub-Continent by 2030, with plans for domestic API production and advanced biological manufacturing.
- The company is pursuing a rights issue of PKR 200 million to enhance working capital and fund capital expenditures.
- Future initiatives include expanding export markets, enhancing digital operations, and pursuing international certifications to access high-value markets.
- The company has a strong market presence in various therapeutic categories and is actively expanding its footprint in Central Asia and the Middle East.